1Sahach VF, Baziliuk OV, Kotsiuruba AV, et al. Disorders of endothelium-dependent vascular reactions and of the arginase and NO-synthase pathways of L-arginine metabolism in arterial hypertension[J]. Fiziol Zh,2000,46(3) :3-13.
2Tesfamariam B. The effects of HMG CoA reductase inhibitors on endothelial function[J]. Am J Cardiovasc Drugs, 2006,6 (2):115-120.
3Lu TM, Ding YA, Leu TB, et al. Effect of rosuvastatin on plasama levels of asymmetric diamethylarginine in patients with hypercholesterolemia[J]. Am J Cardiol, 2004,94 ( 2 ) : 157-161.
4Abbasi F, Asagmi T,Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus[J]. Am J Cardiol, 2001,88(10) : 1201- 1203.
5Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration(CARDIAC) study[J]. Am Heart J,2006,152 (3) :493. el-8.
6Chen JW, Hsu NW, Wu TC, et al. Long-term angiotensin converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X[J]. Am J Cardiol, 2002,90 (9) : 974-982.
7Ascaso J, Gonzalez Santos P, Hernandez Mijares A, et al. Management of dyslipidemia in the metabolic syndrome: recommendations of Spanish HDL Forum[J]. Am J Cardiovasc Drugs,2007,7(1) :39-58.
8Asagami T, Abbasi F, Stuelinger M, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes[J]. Metabolism,2002,81(7):843-846.
9Post MS,Verhoeven MO,van der Mooren MJ,et al. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12 week study in healthy early postmenopausal women[J]. J Clin Endocrinol Metab, 2003,88(9):4221-4226.
10Deedwania PC, Hunninghake DB, Bays HE, et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome[J]. Am J Cardiol,2005,95(3) :360-366.
